Kunchok A, Aksamit Jr AJ, Davis III JM, Kantarci OH, Keegan M, Pittock SJ, Weinshenker BG, McKeon A. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurology 2020;77:agosto. [Ref.ID 103656]

Esse S, Mason KJ, Green AC, Warren RB. Melanoma risk in patients treated with biologic therapy for common inflammatory diseases. A systematic review and meta-analysis. JAMA Dermatol 2020:20 de mayo. [Ref.ID 103629]

Taylor P. BMS completes Celgene merger after FTC okay. PMLiVE 2019:18 de noviembre. [Ref.ID 103210]

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

Anónimo. EMA’s CHMP recommends approval for plaque psoriasis drug. DIA Daily 2018:4. [Ref.ID 102730]

Chiu H-Y, Chang WL, Tai T-F, Tsai Y-W, Shiu M-N. Risk of psoriasis following terbinafine or itraconazole treatment for onychomycosis: a population-based case-control comparative study. Drug Saf 2018;41:marzo. [Ref.ID 102560]

Anónimo. FDA approves guselkumab for treatment of plaque psoriasis. DIA Daily 2017:2. [Ref.ID 101909]

Desai RJ, Bateman BT, Huybrechts KF, Patorno E, Hernández-Díaz S, Park Y, Dejene SZ, Cohen J, Mogun H, Kim SC. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ 2017;356:j895. [Ref.ID 101510]

Anónimo. Ustékinumab et psoriasis chez les adolescents. Prescrire 2016;36:733-4. [Ref.ID 100889]

Anónimo. Sécukinumab et rumatisme psoriasique. Prescrire 2016;36:732. [Ref.ID 100888]

Anónimo. Sécukinumab et psoriasis en plaques. Prescrire 2016;36:727-31. [Ref.ID 100887]

Anónimo. NICE reverses decision, recommends apremilast. DIA Daily 2016:2. [Ref.ID 100805]

Anónimo. Guselkumab effective at clearing moderate to severe psoriasis in clinical trial. DIA Daily 2016:3. [Ref.ID 100775]

Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardis CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016;375:345-56. [Ref.ID 100646]

Anónimo. FDA approves biosimilar version of etanercept. DIA Daily 2016:1. [Ref.ID 100615]

Anónimo. Aprémilast. Prescrire 2016;35:90-4. [Ref.ID 100523]

Anónimo. FDA staff reviewers split over brodalumab’s suicide risk. DIA Daily 2016:1. [Ref.ID 100494]

Anónimo. Ixekizumab (Taltz) - A second IL-17A inhibitor for psoriasis. Med Lett Drugs Ther 2016;58:59-60. [Ref.ID 100347]

Anónimo. FDA advisory panel recommends approval of biosimilar version of infliximab. DIA Daily 2016:1. [Ref.ID 99997]

Anónimo. FDA declines to expand approval of RA drug for treatment of plaque psoriasis. DIA Daily 2015:15 de octubre. [Ref.ID 99558]